Viewing data from:

LYPQOZET

ANDA

ATORVASTATIN CALCIUM; EZETIMIBE | A206084 | PHARMOBEDIENT CONSULTING LLC

4 strengths0 unique patents0 unique exclusivities

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
May 2, 2017	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — EQ 10MG BASE;10MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Apr 26, 2017

No patent or exclusivity listings for this strength.

#002 — EQ 20MG BASE;10MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Apr 26, 2017

#003 — EQ 40MG BASE;10MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Apr 26, 2017

#004 — EQ 80MG BASE;10MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Apr 26, 2017